APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics


APREA THERAPEUTICS, INC. (APRE): $0.50

0.01 (+1.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add APRE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

APRE Stock Price Chart Interactive Chart >

Price chart for APRE

APRE Price/Volume Stats

Current price $0.50 52-week high $2.21
Prev. close $0.50 52-week low $0.30
Day low $0.47 Volume 168,899
Day high $0.50 Avg. volume 305,980
50-day MA $0.43 Dividend yield N/A
200-day MA $0.77 Market Cap 26.58M

APREA THERAPEUTICS, INC. (APRE) Company Bio


Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.


APRE Latest News Stream


Event/Time News Detail
Loading, please wait...

APRE Latest Social Stream


Loading social stream, please wait...

View Full APRE Social Stream

Latest APRE News From Around the Web

Below are the latest news stories about APREA THERAPEUTICS INC that investors may wish to consider to help them evaluate APRE as an investment opportunity.

Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit

DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it will participate in the 6th Annual DDR Inhibitors Summit, held in Boston, Massachusetts from January 24 – January 26, 2023. Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, will participate in a panel discussion entitl

Yahoo | January 19, 2023

Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies

Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.

Yahoo | January 12, 2023

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations. The Phase 1/2a clinical trial is a multi-center, open-label, dose-escal

Yahoo | January 11, 2023

Aprea Therapeutics Inc. (NASDAQ:APRE) Shares Plunges -38.46% In A Week – But Can It Keep Rising?

In last trading session, Aprea Therapeutics Inc. (NASDAQ:APRE) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $0.32 trading at -$0.06 or -15.79% at ring of the bell on the day assigns it a market valuation of $15.57M. That closing price of APRE’s stock is … Aprea Therapeutics Inc. (NASDAQ:APRE) Shares Plunges -38.46% In A Week – But Can It Keep Rising? Read More »

Marketing Sentinel | December 17, 2022

Aprea Therapeutics Inc. (NASDAQ: APRE) Now Carries A 12-Month Price Target Of $3.00.

Aprea Therapeutics Inc. (NASDAQ:APRE)’s traded shares stood at 0.56 million during the last session. At the last check today, the stock’s price was $0.41, to imply a decrease of -21.89% or -$0.11 in intraday trading. The APRE share’s 52-week high remains $5.00, putting it -1119.51% down since that peak but still an impressive -17.07% since … Aprea Therapeutics Inc. (NASDAQ: APRE) Now Carries A 12-Month Price Target Of $3.00. Read More »

Marketing Sentinel | November 11, 2022

Read More 'APRE' Stories Here

APRE Price Returns

1-mo 51.06%
3-mo -26.47%
6-mo -47.37%
1-year -76.08%
3-year -98.70%
5-year N/A
YTD 51.06%
2022 -88.47%
2021 -41.67%
2020 -89.28%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7291 seconds.